The problem is that the trial started in 2015....when sgl2s weren't around, some patients were put on them while BETonMACE was running and if I understand correctly they're inclusion as SOC for some patients had a significant impact on the event rate in the placebo arm.

If BETonMACE were starting now of course these inhibitors would be factored into the trial design....but who knows what other drugs might be added to standard of care next year or the year after....and what impact it might have.